Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Poa Annua Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of grass-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of pollen allergenic extracts used in immunotherapy.
Name
Poa Annua Pollen
Raw Name
POA ANNUA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
13
Variant Count
14
Last Verified
February 17, 2026
About Poa Annua Pollen
Poa Annua Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of grass-pollen-induced allergic rhinitis and conjunctivitis. It belongs to the class of pollen allergenic extracts used in immunotherapy.
Detailed information about Poa Annua Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Poa Annua Pollen.
Poa Annua Pollen, commonly known as Annual Bluegrass Pollen, is a biological substance used in the field of allergy and immunology. Specifically, it is classified as a Non-Standardized Pollen Allergenic Extract [EPC]. This extract is derived from the pollen of Poa annua, a widely distributed grass species found in temperate climates globally. In clinical practice, this extract serves two primary purposes: the diagnosis of hypersensitivity (allergy) to grass pollen through skin testing and the treatment of such allergies through allergen immunotherapy (AIT), often referred to as 'allergy shots.'
As a member of the Poaceae family, Poa Annua is closely related to other common grasses like Kentucky Bluegrass (Poa pratensis), Orchard Grass, and Timothy Grass. Because these grasses share similar protein structures (allergens), patients allergic to one are frequently allergic to others—a phenomenon known as cross-reactivity. The FDA has approved various allergenic extracts, including Poa Annua, for use in patients who exhibit significant allergic symptoms that are not adequately controlled by environmental avoidance or standard pharmacotherapy (such as antihistamines and nasal corticosteroids).
To understand how Poa Annua Pollen works as a therapeutic agent, one must understand the underlying mechanism of Type I hypersensitivity. In an allergic individual, the immune system mistakenly identifies harmless pollen proteins as threats, producing Immunoglobulin E (IgE) antibodies. When the individual is exposed to the pollen again, these IgE antibodies trigger mast cells and basophils to release inflammatory mediators like histamine, leading to sneezing, itching, and congestion.
Poa Annua Pollen immunotherapy works through a process called desensitization or immune tolerance. By administering gradually increasing doses of the allergen, the healthcare provider 'retrains' the patient's immune system. At the molecular level, this involves several complex changes:
Unlike traditional small-molecule drugs (like ibuprofen or lisinopril), allergenic extracts do not follow standard pharmacokinetic pathways of absorption, distribution, metabolism, and excretion. Instead, their 'kinetics' are immunological in nature.
Poa Annua Pollen extract is primarily indicated for:
Poa Annua Pollen is available in several concentrations, usually measured in Weight/Volume (W/V) or Protein Nitrogen Units (PNU). Because it is 'non-standardized,' there is no universal 'Bioequivalent Allergy Unit' (BAU) for this specific extract, making it vital for clinicians to use the same manufacturer's product throughout a patient's treatment to ensure consistency.
> Important: Only your healthcare provider can determine if Poa Annua Pollen is right for your specific condition. Immunotherapy must be administered under the supervision of a physician trained in the management of anaphylaxis.
Dosage for Poa Annua Pollen is highly individualized and follows a two-phase schedule: the Build-up (Escalation) Phase and the Maintenance Phase.
Treatment typically begins with a very dilute solution (e.g., 1:100,000 W/V). Injections are usually administered once or twice weekly. The dose is gradually increased at each visit, provided the patient does not experience significant local or systemic reactions. This phase usually lasts 3 to 6 months.
Once the 'target dose' or 'maintenance dose' is reached (the highest dose the patient can tolerate without a reaction), the interval between injections is increased. Maintenance injections are typically given every 2 to 4 weeks. This phase generally continues for 3 to 5 years to ensure long-lasting immunity.
Poa Annua Pollen extracts are generally considered safe for use in children, typically starting at age 5. Dosing follows the same build-up and maintenance principles as adult dosing, though clinicians may use more conservative escalations in very young children. It is generally not recommended to start immunotherapy in children under age 5 because they may be unable to communicate the early symptoms of a systemic reaction.
No specific dosage adjustments are required for patients with kidney or liver disease, as the extract is not cleared through these organs in a way that affects its safety or efficacy. However, the patient's overall health must be stable before receiving an injection.
Elderly patients (over 65) require careful evaluation. While age itself is not a contraindication, older adults are more likely to have co-existing cardiovascular conditions. If an elderly patient experiences a systemic reaction, their heart may be less able to handle the stress of anaphylaxis or the administration of epinephrine.
Poa Annua Pollen extract for immunotherapy is administered as a Subcutaneous Injection (SCII). It is never injected into a vein or muscle.
If a dose is missed during the build-up phase, the next dose may need to be reduced to prevent a reaction. If a dose is missed during the maintenance phase:
In the context of allergenic extracts, an 'overdose' occurs when a patient receives a dose higher than their current tolerance level. This can lead to a severe systemic allergic reaction or anaphylaxis.
If an overdose is suspected, the immediate administration of epinephrine (adrenaline) is required. The patient should be placed in a supine position (lying flat) with legs elevated, and emergency medical services (EMS) should be summoned.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor of any new medications or changes in your health status.
Most patients undergoing immunotherapy with Poa Annua Pollen will experience some form of Local Reaction. These occur at the site of the injection and are generally not dangerous, though they can be uncomfortable.
> Warning: Stop taking Poa Annua Pollen and call your doctor immediately or go to the nearest emergency room if you experience any of these symptoms of Anaphylaxis:
There are no known long-term 'toxic' effects of Poa Annua Pollen extracts on the organs (such as the liver or kidneys). The primary long-term consideration is the potential for Eosinophilic Esophagitis (EoE), which has been rarely associated with sublingual (under the tongue) forms of grass immunotherapy, though it is less common with the injectable form. Symptoms include difficulty swallowing or food getting stuck in the throat.
While non-standardized extracts like Poa Annua may not always carry a formal 'Black Box Warning' in the same way as standardized extracts (like Timothy Grass), the FDA-approved labeling for all allergenic extracts contains a General Warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider. Keeping a 'symptom diary' of your reactions after each shot can help your allergist adjust your dose safely.
Poa Annua Pollen extract is a potent biological product. Safety depends on the accuracy of the dose and the clinical stability of the patient at the time of the injection. Patients should never receive an injection if they are feeling ill, having an asthma flare-up, or if they have a fever.
No specific FDA black box warning exists for the non-standardized Poa Annua Pollen extract specifically, but it falls under the class-wide warning for all allergenic extracts. This warning emphasizes that these products can cause severe, life-threatening systemic reactions, including anaphylaxis, and must only be administered by physicians prepared to manage such emergencies.
The most significant risk is a systemic allergic reaction. This is more likely to occur if:
Patients with asthma must have their condition well-controlled (e.g., FEV1 > 80% predicted) before receiving a Poa Annua Pollen injection. Immunotherapy can trigger a severe asthma attack in patients with unstable or poorly controlled airway disease.
Patients with significant heart disease may not tolerate the physiological stress of a systemic reaction. Furthermore, the treatment for a reaction (epinephrine) can cause heart strain, arrhythmias, or a heart attack in susceptible individuals.
There are no routine laboratory tests (like blood counts or liver panels) required for Poa Annua Pollen therapy. Instead, monitoring is clinical:
Most patients can drive themselves to and from their appointments. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive and must be monitored in a medical facility. Some patients may feel drowsy if they take an antihistamine before their appointment.
While there is no direct chemical interaction between alcohol and Poa Annua Pollen, alcohol consumption should be avoided for several hours before and after an injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially mask the early signs of a reaction.
Unlike many medications, Poa Annua Pollen does not require a 'taper' to stop. If a patient decides to discontinue immunotherapy, they can simply stop the injections. However, the allergic symptoms will likely return over time if the maintenance phase was not completed (usually 3-5 years).
> Important: Discuss all your medical conditions with your healthcare provider before starting Poa Annua Pollen, especially if you have a history of heart disease or severe asthma.
Beta-blockers are generally considered a major contraindication for allergen immunotherapy. These drugs block the receptors that epinephrine (adrenaline) acts upon. If a patient on a beta-blocker has a severe allergic reaction to Poa Annua Pollen, the standard treatment—epinephrine—may be ineffective. This can lead to 'refractory anaphylaxis,' which is often fatal.
ACE inhibitors can interfere with the body's ability to break down kinins, substances involved in allergic reactions. Patients taking ACE inhibitors may be at a higher risk for more severe or prolonged flushing and low blood pressure during a systemic reaction.
These medications can potentiate the effects of epinephrine, leading to dangerously high blood pressure if epinephrine is needed to treat an allergic reaction from the pollen extract.
While many patients take antihistamines to manage their allergy symptoms, these drugs can 'mask' the early warning signs of a systemic reaction (such as itching or mild hives). If a patient is undergoing diagnostic skin testing, antihistamines must be stopped 3 to 7 days prior, as they will prevent the 'wheal and flare' reaction, leading to a false-negative result.
If a patient is receiving injections for multiple allergens (e.g., dust mites, mold, and Poa Annua), the risk of a systemic reaction is cumulative. Doses may need to be adjusted if multiple injections are given on the same day.
There are no specific food interactions with Poa Annua Pollen. However, patients with 'Oral Allergy Syndrome' (Pollen-Food Allergy Syndrome) may notice that eating certain raw fruits or vegetables (like peaches or celery) triggers itching in the mouth. This is due to cross-reactivity between grass pollen and food proteins, but it does not change how the injection works.
There is no clinical data suggesting interactions between Poa Annua Pollen and common supplements like St. John's Wort or Ginkgo. However, any supplement that affects the immune system or blood pressure should be disclosed to the allergist.
Poa Annua Pollen extract will not interfere with standard blood chemistry or hematology tests. It will, however, affect:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes eye drops and nose sprays, as some may contain beta-blockers.
Patients with an FEV1 (Forced Expiratory Volume) consistently below 70-80% of their predicted value should not receive Poa Annua Pollen injections. The risk of a fatal asthma attack triggered by the injection outweighs the potential benefits of the therapy.
Patients who have had a heart attack or unstable angina within the last 3-6 months are at extreme risk if they experience anaphylaxis. The heart cannot handle the stress of a systemic reaction or the epinephrine required to treat it.
Some extracts contain phenol (a preservative) or glycerin (a stabilizer). If a patient has a documented severe allergy to these specific inactive ingredients, the extract cannot be used.
While some guidelines list this as absolute, others consider it relative if the patient has a life-threatening allergy and no alternative to the beta-blocker exists. However, most allergists will require the patient to switch to a different class of blood pressure medication before starting shots.
There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen an underlying autoimmune disease (like Lupus or Rheumatoid Arthritis). Use in these patients requires a careful risk-benefit analysis.
Patients with active cancer or those undergoing chemotherapy are generally not started on immunotherapy, as their immune systems are compromised or preoccupied with other treatments.
Poa Annua Pollen shows high cross-sensitivity with other members of the Pooideae subfamily. This includes:
If a patient is severely allergic to one of these, they are likely to react to Poa Annua Pollen extract as well.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Poa Annua Pollen.
Allergenic extracts like Poa Annua Pollen have not been studied extensively in pregnant women. The general consensus among allergists (based on AAAAI guidelines) is:
It is generally considered safe to continue Poa Annua Pollen immunotherapy while breastfeeding. The large protein molecules in the extract do not pass into breast milk in any significant quantity, and there is no evidence of harm to the nursing infant. The primary risk remains a systemic reaction in the mother.
As noted previously, immunotherapy is generally not recommended for children under the age of 5. For children 5 and older, it is highly effective and may even prevent the development of asthma later in life (a concept known as the 'Allergic March'). Parents must be vigilant in monitoring the child for several hours after each injection for any signs of hives or coughing.
In patients over 65, the decision to use Poa Annua Pollen must be individualized. The risk of co-morbidities (heart disease, COPD) and the use of multiple medications (polypharmacy) increase the complexity of treatment. Older adults should have a cardiovascular screening (including an EKG) if there is any history of heart issues before starting immunotherapy.
There are no specific restrictions for patients with renal impairment. The extract proteins are not nephrotoxic (toxic to the kidneys) and are not cleared by the kidneys in their active form.
There are no specific restrictions for patients with hepatic impairment. The liver is not involved in the primary 'action' or 'clearance' of allergenic extracts.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.
Poa Annua Pollen extract acts as an immunomodulator. Its primary molecular target is the T-lymphocyte. In an allergic state, T-cells are biased toward a Th2 phenotype, which produces cytokines like IL-4 and IL-5 that stimulate IgE production.
Repeated subcutaneous exposure to Poa annua proteins induces the production of Regulatory T-cells (Tregs). These Tregs secrete IL-10 and TGF-β, which:
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous injection) |
| Protein Binding | N/A |
| Half-life | Minutes to hours (for the proteins) |
| Tmax | 30-60 minutes (for systemic absorption) |
| Metabolism | Proteolytic degradation |
| Excretion | Cellular metabolism |
Poa Annua Pollen is a Non-Standardized Pollen Allergenic Extract. It belongs to the broader category of Allergen Immunotherapy (AIT) agents. It is distinct from 'Standardized' extracts (like Timothy Grass) because its potency is not measured by a federally mandated bioassay, but rather by the weight of the raw material used in the extraction process.
Common questions about Poa Annua Pollen
Poa Annua Pollen extract is primarily used for the diagnosis and treatment of allergies to Annual Bluegrass. In diagnostic settings, it is used in skin prick tests to confirm if a patient is allergic to this specific grass. In therapeutic settings, it is used in allergen immunotherapy (allergy shots) to help desensitize the immune system over time. This treatment is intended for patients with allergic rhinitis, conjunctivitis, or allergic asthma triggered by grass pollen. It is an effective option for those who do not get enough relief from standard allergy medications.
The most common side effects are local reactions at the site of the injection, including redness, swelling, and itching. These reactions are usually mild and disappear within a few hours or a day. Some patients may also experience a temporary increase in their typical allergy symptoms, such as sneezing or watery eyes, shortly after the injection. Fatigue is another commonly reported side effect following the appointment. While rare, serious systemic reactions like hives or difficulty breathing can occur, which is why patients must be monitored for 30 minutes after each dose.
It is generally advised to avoid alcohol for several hours before and after receiving a Poa Annua Pollen injection. Alcohol can cause blood vessels to dilate, which might increase the speed at which the allergen is absorbed into your bloodstream, potentially increasing the risk of a systemic reaction. Additionally, being under the influence of alcohol can make it difficult for you to notice or accurately describe the early symptoms of an allergic reaction. Always consult your allergist for their specific recommendations regarding lifestyle choices during immunotherapy.
Poa Annua Pollen immunotherapy is generally not started during pregnancy due to the risk of a severe allergic reaction, which could harm the developing fetus by reducing oxygen levels. However, if a woman is already on a stable maintenance dose and is tolerating it well, most allergists allow the treatment to continue at that same dose. The dosage is typically not increased until after delivery. If you are planning to become pregnant or find out you are pregnant while on allergy shots, you must inform your healthcare provider immediately to discuss the safest course of action.
Immunotherapy with Poa Annua Pollen is a long-term commitment and does not provide immediate relief like an antihistamine. Most patients begin to notice a reduction in their allergy symptoms after they reach the maintenance phase, which usually takes 3 to 6 months of weekly injections. Significant improvement is typically seen during the first grass pollen season after reaching maintenance. For the best and most long-lasting results, the treatment is usually continued for a total of 3 to 5 years. This allows the immune system to fully develop a long-term tolerance to the pollen.
Yes, you can stop taking Poa Annua Pollen injections suddenly without experiencing withdrawal symptoms, as it is not a physically addictive medication. However, stopping the treatment prematurely, especially before completing the maintenance phase, will likely result in the return of your allergy symptoms over time. The 'disease-modifying' benefits of immunotherapy are only achieved through consistent, long-term exposure to the extract. If you are considering stopping your shots due to side effects or scheduling issues, talk to your allergist first, as they may be able to adjust your protocol.
If you miss a dose of Poa Annua Pollen, you should contact your allergist's office to reschedule as soon as possible. The procedure for a missed dose depends on how long it has been since your last injection and whether you are in the build-up or maintenance phase. If you are in the build-up phase, your doctor may need to repeat the previous dose or even go back a few steps to ensure safety. During the maintenance phase, a short delay of a week or two is usually fine, but longer delays will require a temporary dose reduction to prevent a reaction when you resume.
There is no clinical evidence to suggest that Poa Annua Pollen allergenic extracts cause weight gain. The extract consists of natural proteins and a small amount of stabilizer (like glycerin or phenol), none of which have metabolic effects that would lead to increased body fat or water retention. If you experience weight changes while on immunotherapy, it is likely due to other factors such as diet, lifestyle, or other medications you may be taking (such as oral corticosteroids for asthma). Discuss any concerns about weight with your primary care physician.
Poa Annua Pollen can be taken alongside most common medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers, as these can make an allergic reaction much more dangerous and difficult to treat. ACE inhibitors and MAO inhibitors also require careful monitoring. Most patients continue to take their regular allergy medications, like antihistamines and nasal sprays, while receiving shots. In fact, these medications can help manage the minor side effects of the immunotherapy itself.
The concept of 'generic' vs. 'brand name' is slightly different for allergenic extracts than for pills. Poa Annua Pollen is a biological product produced by several different specialized laboratories (such as ALK, Greer, or HollisterStier). While the extracts are essentially the same biological material, they are not considered interchangeable 'generics' because they are non-standardized. This means the potency can vary between manufacturers. Once you start treatment with a specific manufacturer's extract, your allergist will generally stick with that same source to ensure your dosage remains consistent and safe.